08D.F MIRUM PHARMAC. DL-0001
- Market cap
- EUR 5.44B
- P/E
- -
- P/B
- 25.24x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 08D.F undervalued?
Graham numberThe Graham number of MIRUM PHARMAC. DL-0001 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MIRUM PHARMAC. DL-0001 fundamental analysis
No fundamental analysis for MIRUM PHARMAC. DL-0001 yet.
MIRUM PHARMAC. DL-0001 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MIRUM PHARMAC. DL-0001
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved …
Full company profileMIRUM PHARMAC. DL-0001 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
MIRUM PHARMAC. DL-0001 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 19.1M | 77.1M | 186M | 337M | 521M | 696M |
| Gross Profit | 17.2M | 64.7M | 139M | 255M | 421M | 570M |
| Operating Income | -173M | -131M | -109M | -87.6M | -22.1M | -181M |
| EBITDA | - | -123M | -136M | -49.0M | 17.2M | -1.16B |
| Net Income | -84.0M | -136M | -163M | -87.9M | -23.4M | -1.20B |
| EPS | -2.75 | -3.67 | -3.50 | -1.82 | -0.45 | -18 |
| Balance Sheet | ||||||
| Total Assets | 295M | 353M | 647M | 671M | 843M | 1.03B |
| Total Liabilities | 174M | 211M | 398M | 445M | 528M | 1.08B |
| Shareholders' Equity | 120M | 142M | 249M | 226M | 315M | -54.2M |
| Cash & Short-term Investments | 31.3M | 28.0M | 286M | 223M | 297M | 243M |
| Cash Flow | ||||||
| Operating Cash Flow | -133M | -120M | -70.9M | 10.3M | 55.8M | -370M |
| Capital Expenditure | 19.0M | 278K | 20.1M | 21.0M | 954K | 49.3M |
| Free Cash Flow | -152M | -120M | -91.1M | -10.7M | 54.9M | -419M |
| Ratios | ||||||
| ROE | -69.9% | -95.5% | -65.7% | -39.0% | -7.4% | - |
| ROA | -28.5% | -38.4% | -25.3% | -13.1% | -2.8% | -116.6% |
| Net Profit Margin | -438.9% | -176.0% | -87.7% | -26.1% | -4.5% | -172.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
MIRUM PHARMAC. DL-0001 dividends
MIRUM PHARMAC. DL-0001 has not paid dividends in the last 5 fiscal years.
Who owns MIRUM PHARMAC. DL-0001
- Insiders 1.31%
- Institutions 98.69%
- Public & others 0.00%
- Shares outstanding 65.3M
- Free float 56.7M
MIRUM PHARMAC. DL-0001 company profile
- Company name
- MIRUM PHARMAC. DL-0001
- Ticker
- 08D.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 470
- Fiscal year end
- December
- Address
- 989 East Hillsdale Boulevard, Foster City, CA, United States, 94404
- Phone
- 650 667 4085
- Website
- mirumpharma.com
About MIRUM PHARMAC. DL-0001
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases; Brelovitug, for the treatment of chronic HDV infection, which is in Phase 2 clinical trial; and MRM-3379, that is in Phase 2 clinical study for the treatment of FXS. The company has a collaboration agreement with the Shire International GmbH; License Agreement with Pfizer Inc.; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC and Dart Neuroscience LLC; Asset Purchase Agreement with Asklepion Pharmaceuticals, LLC; License and Manufacturing Agreement with LGM Pharma; and Asset Purchase Agreement with Travere Therapeutics, Inc. The company was incorporated in 2018 and is headquartered in Foster City, California.
MIRUM PHARMAC. DL-0001 management
10- Mr. Christopher PeetzCEO & Director · born 1979
- Mr. Peter Radovich M.B.A., Ph.D.COO & President · born 1978
- Mr. Eric H. Bjerkholt M.B.A., M.S.Chief Financial Officer · born 1960
- Dr. Jean-Luc Girardet Ph.D.Chief Technical Officer
- Mr. Andrew McKibbenSenior Vice President, Strategic Finance & Investor Relations
- Mr. Douglas T. Sheehy J.D.Chief Legal Officer & Secretary · born 1967
- Meredith KiernanSenior Director of Global Corporate Communications
- Ms. Erin CampanyChief People Officer · born 1968
- Ms. Lara Longpre MBA, MSCChief Development Officer · born 1970
- Ms. Vinita P. KumarSenior Vice President of Quality